Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +25.20%
#2 aelf aelf +23.74%
#3 Bitway Bitway +16.31%
#4 Decred Decred +11.24%
#5 TRIA TRIA +8.49%
#6 Wibx Wibx +8.11%
#7 Pons Pons +7.97%
#8 DexNet DexNet +7.55%
#9 Status Status +7.12%
#10 AtomOne AtomOne +7.07%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Settings
Language
ENGLISH
Currency
USD
Theme
Argenica Therapeutics Ltd Argenica Therapeutics Ltd

Argenica Therapeutics Ltd

AGN
Rank in Stocks #30341
Argenica Therapeutics Limited, a biotechnology company, engages in the research... Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drugs in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in phase 2 clinical trial to reduce brain tissue death after stroke and other types of brain injury. The company was incorporated in 2019 and is based in Nedlands, Australia.
Share Price
$0.13400411
Market Cap
$17.21M
Change (1 day)
-7.32%
Change (1 year)
-70.34%
Country
AU
Trade Argenica Therapeutics Ltd (AGN)

Category

Healthcare
P/E ratio for Argenica Therapeutics Ltd (AGN)
P/E ratio as of 2026 TTM: 0
According to Argenica Therapeutics Ltd latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Argenica Therapeutics Ltd from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 18.38 -
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.